Insights That Move the GPCR Field Forward

Most biotech founders assume that failure comes from making the wrong call. A flawed experiment. A bad hire. A missed partnership. 👉 Biotech startup failure is usually imagined as a moment where something clearly breaks. In reality, many biotech startups drift into trouble without ever making a single decision that looks wrong at the time. Progress continues. Data improves. Teams stay busy. And yet, momentum slowly fades. 👉 This is what makes biotech startup failure so diff

👉 Most biotech founders experience that external conversations consume more energy than they should . Investor calls take too long before reaching substance. Partner discussions sound positive but rarely lead to concrete next steps. Business development conversations feel inconsistent, even when the company and the science have not changed. 👉 The natural reaction is to improve communication. Founders refine their pitch, rewrite slides, and rehearse explanations. Yet better

👉 In early-stage biotech , uncertainty is not an exception. It is the environment. The science evolves, assumptions break, and timelines shift quietly rather than dramatically. Most founders are prepared for this on a technical level. What they are less prepared for is how much this uncertainty tests the team. Early hiring decisions are usually made around skills, experience, and domain expertise. That feels logical. 👉 Complex biology seems to demand strong credentials.  Bu

Burning Cash Isn’t the Problem. Burning Alignment Is. Every biotech founder fears the day the cash runs out. You track the burn rate. You watch the runway shrink. You delay hires. You negotiate term sheets from a place of panic. But here’s what most founders miss. 👉 Cash isn’t your biggest problem. Misalignment is. Not the obvious kind either. We’re not talking about personality clashes or investor drama. 👉 We’re talking about the type of quiet misalignment that appears to